Effect of Serum Containing Huiyao Aikang Formula on Apoptosis of Human Lung A549 Cells

MA Ke; MA Zhi-guo; ZHOU Hui; BIAN Jing; WU Zhen; ZHANG Li-na; ZHOU Li-ping; JI Xiu-e

doi:10.13422/j.cnki.syfjx.2014100146

您当前的位置：

首页 >

文章列表页 >

Effect of Serum Containing Huiyao Aikang Formula on Apoptosis of Human Lung A549 Cells

更新时间：2024-01-04

- Effect of Serum Containing Huiyao Aikang Formula on Apoptosis of Human Lung A549 Cells
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 20, Issue 10, Pages: 146-150(2014)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2014100146
  CLC： R285.5
- Published：2014
- 稿件说明：
移动端阅览
MA Ke, MA Zhi-guo, ZHOU Hui, et al. Effect of Serum Containing Huiyao Aikang Formula on Apoptosis of Human Lung A549 Cells [J]. Chinese journal of experimental traditional medical formulae, 2014, 20(10): 146-150.
DOI：

MA Ke, MA Zhi-guo, ZHOU Hui, et al. Effect of Serum Containing Huiyao Aikang Formula on Apoptosis of Human Lung A549 Cells [J]. Chinese journal of experimental traditional medical formulae, 2014, 20(10): 146-150. DOI： 10.13422/j.cnki.syfjx.2014100146.

摘要

目的：探讨回药爱康方（HAKF）含药血清对人肺腺癌A549细胞凋亡的影响。方法：SD大鼠随机分为对照组、爱康方低、中、高剂量组、环磷酰胺（CTX）组、回药爱康方低、中、高剂量分别联合环磷酰胺化疗组，药物低、中、高剂量15.0，30.0，45.0 g·kg-1，连续灌胃15 d，麻醉后心脏取血，制备含药血清。培养细胞，将细胞分为实验组和对照组，实验组分别给予含5%，10%，20%3个体积分数的相应各组含药血清，对照组给予等体积分数的对照组大鼠血清，培养24，48，72 h后采用Annexin-VFITC/PI双染法测定各组含药血清对A549细胞凋亡的影响。结果：与对照组比较，各时段5%，10%，20%浓度含药血清可提高A549的凋亡率（P<0.05），72 h时，各浓度回药爱康方低、中、高剂量含药血清对细胞的凋亡率的提高程度小于CTX（P<0.05）；72 h 10%体积分数回药爱康方低剂量联合环磷酰胺血清提高细胞的凋亡率大于单纯CTX（P<0.05）；各浓度爱康方中剂量和高剂量血清组，72 h与24 h比较，两组A549细胞的凋亡率均升高（P<0.05）；随着血清体积分数的提高，各组细胞的凋亡率和坏死率呈增大趋势。结论：回药爱康方可诱导人肺腺癌A549细胞的凋亡，且有一定的剂量和时间依赖性。

Abstract

Objective: To observe the effect of serum containing Huiyao Aikang formula on apoptosis of human lung A549 cells in vitro. Method: SD rats were divided into low

medium

high dose Huiyao Aikang formula groups

cyclophosphamide(CTX) group;low

medium

high dose combined with CTX group

and normal saline group.The serum containing Huiyao Aikang formula was prepared. The cells were divided into treatment and control groups

the treatment groups were treated with 5%

10%

20% containing drug serum

control group was given the same concentration of control serum

at 24

72 h the proliferation of A549 was measured by MTT method. The apoptosis rate was measured with flow cytometry(FCM). Result: Compared with control group

apoptosis rates in 5%

10%

20% containing drug serum groups were increased'(P<0.05). At 72 h

the apoptosis rate in low

middle

high dose of Huiyao Aikang formula groups was lower than that in CTX groups.(P<0.05); Conclusion: Huiyao Aikang formula can induce apoptosis of human lung adenocarcinoma A549 cells.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Stemona tuberosa Alkaloids on Apoptosis and PI3K/Akt and JNK/MAPK Signaling Pathways of Human Lung Cancer A549 Cells

Effect of Xiancidan on Apoptosis and Cycle of non-small Cell Lung Cancer A549

Influence of Guantong Fang and Its Disassembled Prescription Medicated Serum on Apoptosis of Rat Vascular Smooth Muscle Cells

Effect of Yiqi Tongluo Jiedu Recipe and Gefitinib Medicated Serum on Proliferation and Apoptosis of Lung Cancer H1975 Cells

Treatment of Sepsis-induced Inflammatory Responses with Xijiao Dihuangtang by Modulation of PKM2-mediated One-carbon Metabolism Pathway

Related Author

LIN Si

QIN Huizhen

LI Zeyu

XU Liba

DENG Lingyu

LUO Jing

XIE Fengfeng

ZHANG Miao

Related Institution

Guangxi University of Chinese Medicine

Guangxi Key Laboratory of Zhuang and Yao Ethnic Medicine， Guangxi University of Chinese Medicine

Affiliated Hospital of Nanjing University of Chinese Medicine

The First Clinical Medical College，Nanjing University of Chinese Medicine

Jiangsu Province Hospital of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰